Hyperhomocysteinemia is an independent risk factor in young patients with coronary artery disease in southern China

Herz

Volumn 38, Issue 7, 2013, Pages 779-784

  Wu, Y ^a   Huang, Y ^a   Hu, Y ^a   Zhong, J ^a   He, Z ^a   Li, W ^a   Yang, Y ^a   Xu, D ^a   Wu, S ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Coronary artery disease; Homocysteine; Risk factors; Southern China; Young

Indexed keywords

C REACTIVE PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SMOKING;

BIOLOGICAL MARKERS; CHINA; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84902536656     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-013-3761-y     Document Type: Article

References (29)

1. Huang Y, Hu Y, Mai W et al (2011) Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease. Dis Markers 31:295-301
2. Eichler K, Puhan MA, Steurer J, Bachmann LM (2007) Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 153:722-731, 731.e1-8
3. Zarich S, Luciano C, Hulford J, Abdullah A (2006) Prevalence of metabolic syndrome in young patients with acute MI: does the Framingham risk score underestimate cardiovascular risk in this population. Diab Vasc Dis Res 3:103-107 (Pubitemid 44638384)
4. Helfand M, Buckley DI, Freeman M et al (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151:496-507
5. Kampoli AM, Tousoulis D, Papageorgiou N et al (2012) Clinical utility of biomarkers in premature atherosclerosis. Curr Med Chem 19:2521-2533
6. Veeranna V, Zalawadiya SK, Niraj A et al (2011) Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 58:1025-1033
7. Clarke R, Halsey J, Bennett D, Lewington S (2011) Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J Inherit Metab Dis 34:83-91
8. Holmes MV, Newcombe P, Hubacek JA et al (2011) Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 378:584-594
9. Clarke R, Halsey J, Lewington S et al (2010) Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 170:1622-1631
10. Cho DY, Kim KN, Kim KM et al (2012) Combination of high-sensitivity C-reactive protein and homocysteine may predict an increased risk of coronary artery disease in Korean population. Chin Med J (Engl) 25:569-573
11. McCullough PA, Li S, Jurkovitz CT et al (2008) Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J 156:277-283
12. Oudi ME, Aouni Z, Mazigh C et al (2010) Homocysteine and markers of inflammation in acute coronary syndrome. Exp Clin Cardiol 15:e25-28
13. Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560-2572 (Pubitemid 37430158)
14. (o A) (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5-20
15. The Association Committee of Prevention and Treatment of Dyslipidemia (2007) The 2007 guidelines for prevention and treatment of dyslipidemia in adults in China. Chin J Cardiol (Chin) 35:390-419
16. Logue J, Thompson L, Romanes F et al (2010) Management of obesity: summary of SIGN guideline. BMJ 340:c154
17. Cui H, Wang F, Fan L et al (2011) Association factors of target organ damage: analysis of 17,682 elderly hypertensive patients in China. Chin Med J (Engl) 124:3676-3681
18. Talbert RL (2002) New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III. Am J Manag Care 8(12 Suppl):S301-307
19. Smith SC Jr (2006) Current and future directions of cardiovascular risk prediction. Am J Cardiol 97:28A-32A
20. Antoniades C, Antonopoulos AS, Tousoulis D et al (2009) Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 30:6-15
21. Banos-Gonzalez MA, Angles-Cano E, Cardoso-Saldana G et al (2012) Lipoprotein(a) and homocysteine potentiate the risk of coronary artery disease in male subjects. Circ J 76:1953-1957
22. Di MMN, Tremoli E, Coppola A et al (2010) Homocysteine and arterial thrombosis: challenge and opportunity. Thromb Haemost 103:942-961
23. Kampoli AM, Tousoulis D, Papageorgiou N et al (2012) Clinical utility of biomarkers in premature atherosclerosis. Curr Med Chem 19:2521-2533
24. Cho DY, Kim KN, Kim KM et al (2012) Combination of high-sensitivity C-reactive protein and homocysteine may predict an increased risk of coronary artery disease in Korean population. Chin Med J (Engl) 125:569-573
25. Nagele P, Meissner K, Francis A et al (2011) Genetic and environmental determinants of plasma total homocysteine levels: impact of population-wide folate fortification. Pharmacogenet Genomics 21:426-431
26. Schneider JA, Rees DC, Liu YT, Clegg JB (1998) Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 62:1258-1260 (Pubitemid 28199029)
27. Chai HT, Chen YL, Chung SY et al (2011) Value and level of plasma homocysteine in patients with angina pectoris undergoing coronary angiographic study. Int Heart J 52:280-285
28. Perrone-Filardi P, Achenbach S, Mohlenkamp S et al (2011) Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. Eur Heart J 32:1986-1993, 1993a, 1993b
29. Clarke R, Bennett DA, Parish S et al (2012) Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 9:e1001177